Refine by
H2s Articles & Analysis
25 news found
– Company to Webcast Investor Event on September 30th at 8:00 p.m. ET – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
Reporting of top-line data for SAHARA DESERT is planned for H2 ...
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023 Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022 BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced ...
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. ...
Reporting of top-line data is planned for H2 ...
The objectives of the trial remain to assess the safety and immunogenicity of COVIDITY, with study data expected to be available in H2 2022. To date, 22 vaccine-naïve subjects have been enrolled and the COVIDITY immunisations have been well tolerated, with no safety concerns. ...
ByScancell
Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and partnerships Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021 Oramed Pharmaceuticals Inc. ...
Reference Sites: https://www.olansichina.com/what-are-the-features-of-the-best-hydrogen-inhalation-machine-for-hydrogen-therapy-by-inhaling-molecular-hydrogen.html https://www.olansichina.com/news/Hydrogen-Inhalation-Machine.html https://www.olansichina.com/news/High-Purity-H2-Hydrogen-Inhaler.html https://www.olansichina.com/news/Inhaling-Molecular-Hydrogen.html ...
Expected milestones in 2021 & 2022 Phase 2b Investigational New Drug (IND) / Clinical Trial Application (CTA) of EVX-01 in metastatic melanoma – H2 2021. Phase 2b IND / CTA filing for EVX-02 in combination with EVX-03 in adjuvant melanoma – H1 2022. Phase 1a IND / CTA filing for EVX-B1 for S. aureus in skin and soft tissue infections (SSTIs) – ...
The study is planned to start in H2 2021 and will include approximately 100 patients with metastatic gastric cancer. ...
” “Many sufferers take proton pump inhibitors (PPI’s) or H2 blockers to manage their symptoms. However, more than 30% of patients have GERD that is refractory to medications and may have an anatomical problem requiring interventional treatment,” said Peter Janu, MD, a general surgeon at Fox Valley Surgical Associates in Appleton, Wisconsin. ...
The ACTengine® trials continue to recruit according to plan with eight trial sites active in both Europe and the US. A data update is expected in H2 2021 with additional patients being treated, including initial data from patients treated at the target dose. ...
Expected milestones in 2021 Phase 1/2a data on EVX-01 in metastatic melanoma - Q2 2021 Phase 1/2a data on EVX-02 in adjuvant melanoma - Q2 2021 Regulatory filing for clinical trial of EVX-03 in multiple cancers - H2 2021 Fourth Quarter and Full Year 2020 Financial Results Cash position: As of December 31, 2020, cash and cash equivalents were $5.8 million compared to ...
The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral development plan can be found on its dedicated website. ...
In fact Team Delft’s analysis and engineering were so good that they won both the 2020 Shell Eco-marathon Hydrogen Endurance Race with a score of 2506,6 km/kg H2 and the Vehicle Design ...
This exceptional TAR system includes the Hintermann Series H3 (H3) 3-piece, mobile-bearing TAR prosthesis – time-tested globally for over 20 years with consistent, successful results and the Hintermann Series H2 (H2) 2-piece, semi-constrained TAR prosthesis. The H2 is US FDA cleared and the H3 is US FDA approved for the US market and are ...
Beat Hintermann, world-renowned foot and ankle surgeon, developed both the Hintermann Series H3 and the Hintermann Series H2 Total Ankle Replacement Systems. Dr. Hintermann stated, “Since the H3 launch outside of the US (OUS) 18 years ago, it has been a goal of mine to also have the H3 available in the US. ...
” In addition to the H3, mobile-bearing TAR, DTM will continue selling the Hintermann Series H2 (H2), a two-piece, cemented, semi-constrained TAR which received 510(k) clearance to market in November 2017. Surgeons will now have an opportunity, using a single instrument set, to offer a full solution to their patients using the H3 or H2 to ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir® is a fixed-dose combination of the long-acting muscarinic ...